The Charles T. Campbell Eye Microbiology Lab
UPMC | University of Pittsburgh Medical CenterUniversity of Pittsburgh Schools of the Health Sciences
HomeAbout UsLab Diagnostic TestingAntibiotic SusceptibilityAntimicrobial TherapyCurrent ResearchContact Us


2004 OMIG, Abstract 8

OMIG Main Page | 2004 Abstracts | < Previous | Next >

Is ZymarTM (gatifloxacin 0.3%) Better Than CiloxanTM or Fortified Tobramycin in the Treatment of Experimental Gram-Negative Keratitis?
FS Mah, RP Kowalski, EG Romanowski, KA Yates, BR Kowalski, YJ Gordon. The Charles T. Campbell Laboratory, University of Pittsburgh, Pittsburgh, PA

Purpose: To compare the efficacy of Zymar™ (gatifloxacin 0.3%), Ciloxan™ (ciprofloxacin 0.3%) and 1.4% (14 mg/ml) fortified Tobramycin (TOB) in the treatment of experimental Gram-negative bacterial infections of quinolone-susceptible Serratia marcescens (SM) and Pseudomonas aeruginosa (PA) in the NZW rabbit keratitis model.
Methods: In separate but identical experiments, done in duplicate trials, a total of 30 NZW rabbits were intrastomally inoculated in both eyes with approximately 1,000 (1.0 x 103) cfu/eye in 25 ul. After 16 hours, the rabbits were divided into the 4 treatment groups (n=6 rabbits per group): 1) Zymar, 2) Ciloxan, 3) TOB and 4) saline control. One drop was instilled in both eyes every 15 minutes for 5 doses then, every 30 minutes for 14 doses (19 total doses over 8 hr). In addition, 6 rabbits were euthanized at 16 hours to determine the number of corneal colony counts at the onset of therapy. One hour after the final treatment, the animals were euthanized and corneal colony counts determined. The first experiment utilized a clinical isolate of SM (MICs [ug/ml]: Gat 0.125; Cip 0.047; TOB 1.5). The second experiment utilized the clinical isolate of PA (MICs [ug/ml]: Gat 0.125; Cip 0.19; TOB 0.5).
Results: In the SM experiment, Zymar (0.8 ± 1.3) (mean ± sd Log10 cfu/ml) and Ciloxan (3.2 ± 1.6) significantly decreased the number SM colony counts compared with TOB (7.2 ± 0.6) and the saline control (7.6 ± 0.6) (p = 0.000, power = 1.0). Zymar also significantly decreased the number of SM colony counts compared with Ciloxan (p = 0.000, power = 1.0). Zymar (-6.4 Logs) and Ciloxan (-4 Logs) decreased colony counts compared with the onset of therapy control, whereas TOB did not. In the PA experiment, Zymar (1.8 ± 2.1), Ciloxan (1.7 ± 1.8), and TOB (1.8 ± 1.5) significantly decreased the number of PA colony counts compared with the saline control (5.3 ± 0.8) (p = 0.000, power =0.9999). There were no differences in PA colony counts among Zymar, Ciloxan, and TOB. Zymar (-1.8 Logs), Ciloxan (-1.9 Logs), and TOB (-1.8 Logs) decreased colony counts compared with the onset of therapy control.
Conclusions: Only Zymar™ and Ciloxan™ were effective in reducing the number of SM corneal colony counts in the NZW rabbit keratitis model with Zymar™ being significantly more effective than Ciloxan™. In contrast, Zymar™, Ciloxan™, and TOB were equally effective in reducing the number of PA corneal colony counts in the NZW rabbit keratitis model. Zymar™ may prove to be a valuable clinical treatment of PA and SM keratitis. Only clinical trials can prove whether Zymar™ is an effective treatment for PA and SM keratitis in patients.

Disclosure code: F, C
Support: Allergan, Inc., EY08098, Eye & Ear Foundation, and RPB

OMIG Main Page | 2004 Abstracts | < Previous | Next >

Top of Page


Web Site Terms of Use | E-mail Terms of Use | Medical Advice Disclaimer
UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences | Contact UPMC